Optomec Partners with Tesscorn to Expand Additive Manufacturing Market in India

Tesscorn to Distribute Optomec LENS Systems for 3D Printed Metals and Aerosol Jet Systems for 3D Printed Electronics

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Optomec, a leading global supplier of production grade additive manufacturing systems for 3D printed metals and 3D printed electronics, today announced it signed a distribution agreement with Tesscorn Nano Science, Inc. to expand sales of its solutions into India. Tesscorn is a leading distributor of integrated products, services, and support to the research and development community in India including Defense, Aerospace, Automotive, Military Forces and Universities.

Optomec Aerosol Jet printers provide high-resolution 3D printing capabilities required to manufacture smaller, lighter-weight, high-performance devices used in industries such as Aerospace, Defense, Consumer Electronics and the Internet of Things (IoT). Aerosol Jet technology is scalable for high volume production applications. The advanced printing technology uses patented aerodynamic focusing to precisely print electronic circuitry and functional components in dimensions ranging from as small as 10 microns to as large as several millimeters in a single pass. Click here for more information on the Aerosol Jet technology.

Optomec LENS printers use the energy from a high-power laser to build up structures one layer at a time, directly from powdered metals. The LENS process can completely build new metal parts or add material to existing metal components for repair and hybrid manufacturing applications. LENS technology is available in standalone system configurations or as a modular print engine for integration with CNC automation platforms. Click here for more information on LENS addition manufacturing technology.

Ramesh Athihalli, Director, Tesscorn Nano Science, Inc., stated:

We at Tesscorn, are excited to partner with Optomec to distribute 3D Printing/additive manufacturing technology in India. Our objective is to lead the digital revolution by empowering product designers and engineers to witness their innovations much faster than before and to empower India’s advanced manufacturing technology. Automation is spreading to every production line in India, and 3D printing is part of that trend. We at Tesscorn want to be an integral part of this revolution. The Aerosol Jet and LENS technology from Optomec are revolutionary technologies in this exciting field of 3D printing/additive manufacturing and our team at Tesscorn are dedicated towards adoption of these technologies to the huge bank of opportunities across various research and manufacturing industries in India.

“Over the past 25 years, Tesscorn has established itself as a leader in supplying advanced manufacturing technology for production and research use in India,” said Michael Kardos, Optomec Vice President of Worldwide Sales. “With their success in our target markets, we believe they can help expand the adoption of Optomec additive manufacturing solutions throughout India.”

About Tesscorn

Tesscorn Nano Science, Inc. was founded in 1993. The company has built its reputation as a leading supplier of top quality instrumentation for institutions in the Semiconductor, Solar and Nanotechnology manufacturing and research sectors. Over the years they have developed a network of suppliers, all leaders in their fields, providing unique manufacturing and research technologies across a broad spectrum of applications.

About Optomec

Optomec is a privately-held, rapidly growing supplier of production grade Additive Manufacturing systems. Optomec's patented Aerosol Jet systems for printed electronics and LENS 3D Printers for metal components are used by industry to reduce product cost and improve performance. Together, these unique printing solutions work with the broadest spectrum of functional materials, ranging from electronic inks to structural metals and even biological matter. Optomec has more than 300 marquee customers around the world, targeting production applications in the Electronics, Energy, Life Sciences and Aerospace industries.

LENS (Laser Engineered Net Shaping) is a registered trademark of Sandia National Laboratories. Aerosol Jet is a registered trademark of Optomec Inc.

Twitter- https://twitter.com/optomecinc
Facebook- www.facebook.com/optomec
LinkedIn- https://www.linkedin.com/company/optomec


Shayna Watson, 505-761-8250

Cognate Completes Management Buyout and Raises Growth Capital to Fund Commercial Cellular Therapy Manufacturing Expansion

BALTIMORE & MEMPHIS, Tenn.--(BUSINESS WIRE)--Cognate BioServices, a leading contract development and manufacturing organization (“CDMO”) in the global cellular therapies industry, announced today it has completed a management buyout (“MBO”) and raised capital from a group of global investment firms including Santa Monica, Calif.-based Tennenbaum Capital Partners, LLC (“TCP”), Medivate Partners and affiliates (“Medivate”) based in Seoul, South Korea and a sovereign wealth fund.

“As an early investor in Cognate, we are very excited to expand our partnership with the company,” said Dan Worrell, Managing Director of TCP. “For the past two decades, TCP’s healthcare strategy has focused on investing in companies that improve healthcare by lowering costs or facilitating improved patient access and outcomes. Cognate provides critical cost-effective support to small, medium, and large biotech companies on the forefront of personalized medicine. We are pleased to continue our participation in funding their growth and expansion.”

With a successful track record in manufacturing products for innovative therapeutic drugs in oncology and regenerative medicine (on behalf of its clients and partners), Cognate is one of the only CDMOs capable of handling the personalized products that are being approved by regulators today. The company recently opened up new manufacturing capacity to support products for both the E.U. and the U.S. in Memphis, Tennessee, and is well on its way to being able to support commercial scale production. The transaction includes significant growth capital to accelerate Cognate’s second phase of commercial expansion that began in 2015.

“This transaction is the culmination of years of planning and execution on the part of our highly collaborative and dedicated team with committed investors who came together to make this a reality,” according to J. Kelly Ganjei, CEO of Cognate BioServices, Inc. “We are excited to have completed the second phase of our growth strategy and look forward to further demonstrating our compelling and unique value proposition to the cell therapy market.”

The MBO and capital raise will accelerate Cognate’s commercial activities for clients and prospects, secure the company’s future as a leading CDMO in the emerging cellular therapies space and provide a clear path to commercialization.

“Our investment was driven by a combination of the tremendous opportunity in personalized cell therapy manufacturing and our confidence in the strong management team at Cognate,” said Medivate’s Managing Partner Roger Kang. “We are very excited to be a part of this syndicate and look forward to being part of their continued growth.”

About Cognate BioServices

Cognate BioServices is a fully-integrated contract bioservices organization providing the highest level of scientific and management expertise. Cognate provides full development and cGMP manufacturing services to companies and institutions engaged in the development and manufacture of cell-based products. The combination of highly experienced staff, successful track records and cGMP facilities makes Cognate one of the most qualified contract manufacturers of cell-based products in the world today.

About Tennenbaum Capital Partners, LLC

Tennenbaum Capital Partners, LLC ("TCP") is an alternative investment management firm with approximately $9 billion of committed capital focused on direct lending and special situations for middle-market companies. TCP manages funds and accounts on behalf of global institutional investors. Since its founding in 1999, TCP has invested approximately $19 billion in over 500 companies. TCP is headquartered in Los Angeles with additional offices in Atlanta, New York and San Francisco. For more information, please visit: www.tennenbaumcapital.com and www.tcpcapital.com.

About Medivate Partners

Medivate, is a private equity and venture capital firm that focuses investment in biotech/healthcare industry in Asia and North America. The firm is well positioned to capture surging healthcare investment opportunities between Asia and North America, and looks to arbitrage the unique cross border investment advantages. While closing its third fund, Medivate Partners quickly built a reputation for providing inner circle access to top caliber syndicates and successful life science deals in Asia and North America.


For Cognate BioServices
Elasticity for Cognate BioServices
Aaron Perlut, 314-800-7218
For Tennenbaum Capital Partners, LLC
Tennenbaum Capital Partners, LLC
Katie McGlynn, 310-899-4948
Financial Profiles
Tricia Ross, 310-622-8226

Global & US Gene Therapy Market Forecast to 2018-2020: Rising Focus to Accelerate Commercialization of Gene Therapy in Developed Nations – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global & US Gene Therapy Market Forecast to 2020" report has been added to ResearchAndMarkets.com's offering.

According to the report, most of the gene therapy researches are being focused on finding the treatment for cancer, followed by genetic diseases and neurological disorders, respectively. In this context, the gene therapy application chapter of the report provides a comprehensive overview of various diseases in which the gene therapy is used, along with the current and future market size of gene therapy for particular disease and its geographical break up.

The major part of the revenue of gene therapy market is generated from the research phase. Most of the gene therapy products are in research phases, only few products have been commercialized till date. The report also provides the sales of major marketed gene therapy products, and the list of the products in clinical/pre-clinical research along with their clinical phases.

North America continues to have the maximum number of clinical trials in the gene therapy segment. This is a major reason for the dominant position of North America in the gene therapy market.

Key Topics Covered:

1. Research View

2. Research Methodology

3. Gene Therapy - An Introduction

4. Industry Overview

5. Clinical Trial Assessment & Pipeline Analysis

6. Gene Therapy Market - Regulatory Landscape & Reimbursement Scenario

7. Marketed Gene Therapies

8. Gene Therapy Market

9. Gene Therapy Market by Application

10. Gene Therapy Market Size by Geography

11. Competitive Landscape

12. Key Players Analysis

  • Companies Mentioned
  • Advantagene Inc.
  • Bluebird Bio
  • Genethon
  • Human Stem Cells Institute
  • Oxford BioMedica Plc
  • Sanofi
  • Shanghai Sunway Biotech Co. Ltd.
  • Sibiono GeneTech Co. Ltd.
  • Spark Therapeutics, LLC
  • uniQure N.V.
  • Vical Inc.
  • ViroMed Co. Ltd. dba VM BioPharma

For more information about this report visit https://www.researchandmarkets.com/research/tkqxw5/global_and_us?w=4.


Laura Wood, Senior Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics

Reliance Industries Limited to Acquire Stake in Eros International PLC

Announces Joint Partnership with Eros India to set-up a $150 million fund to co-produce and consolidate content

Jyoti Deshpande to head RIL’s media and entertainment business as President of the Chairman’s Office

MUMBAI, India--(BUSINESS WIRE)--Reliance Industries Limited (“RIL”) and Eros International PLC (“Eros”) announced today that RIL, through a subsidiary, has agreed to subscribe to a 5% equity stake in NYSE listed Eros at a price of $15.00 per share, which represents an 18% premium to last closing price. The transaction is subject to customary regulatory and other approvals.

Furthermore, RIL and Eros International Media Limited (“Eros India”) announced that they have agreed to partner in India to jointly produce and consolidate content from across India. The parties will equally invest up to approximately $150 million to produce and acquire Indian films and digital originals across all languages.

In addition, it was announced that Ms. Jyoti Deshpande, Group CEO and MD of Eros will be stepping down from her Executive role after more than 17 years in Eros and move on to head the Media and Entertainment business at RIL as President of the Chairman’s Office. Ms. Deshpande will start her role at RIL from April 2018, but will continue to remain as a Non-Executive Director on the Board of Eros. Mr. Kishore Lulla will resume his position of Group Chairman and CEO of Eros.

In her new role at RIL, Ms. Deshpande will lead the company’s initiatives in Media and Entertainment to organically build and grow businesses around the content ecosystem such as Broadcasting, Films, Sports, Music, Digital, Gaming, Animation etc., as well as integrate RIL’s existing media investments such as Viacom and Balaji Telefilms with a view to build, scale and consolidate the fragmented $20 billion Indian M&E sector.

Mukesh Ambani, Chairman & Managing Director, RIL commented, “We are pleased to join hands with Eros, as it will bring further synergies into our plans, making for a win-win partnership. We are delighted to welcome Ms. Jyoti Deshpande into the Reliance family and believe that she will not only give wings to our plans but also play a pivotal role in transforming the sector.”

Commenting on the development Mr. Kishore Lulla said, “I am very pleased that Eros is partnering with RIL in its entertainment journey with several synergies across technology, content and digital with Eros Now. We look forward to collaborating and growing as we continue to make new strides on the digital and content forefronts. I am confident that together, we can make a meaningful difference. Jyoti Deshpande has been an invaluable part of the incredible Eros growth journey and I am confident that she will make a positive impact on the industry in her new role at RIL. I wish her the very best of luck.”

Ms. Jyoti Deshpande commented, “Having worked and associated with Eros group since 1998, it has been an integral part of my professional career and I extend my heartfelt thanks to Kishore Lulla and the Eros family for the opportunity to build an amazing company together. I am delighted that RIL has strategically aligned with Eros, so the association continues. My new assignment at RIL will allow me to push boundaries, set new standards of excellence, assemble a world-class young leadership team and adopt a collaborative approach to architect and execute this ambition in true RIL tradition. I am genuinely honored and humbled to have been granted this opportunity but more than anything I cannot wait to roll up my sleeves.”

About RIL

RIL is India’s largest private sector company, with a consolidated turnover of INR 330,180 crore (USD 50.9 billion), cash profit of INR 42,800 crore (USD 6.6 billion), and net profit of INR 29,901 crore (USD 4.6 billion) for the year ended March 31, 2017.

RIL is the first private sector company from India to feature in Fortune’s Global 500 list of ‘World’s Largest Corporations’ – currently ranking 203rd in terms of revenues, and 110th in terms of profits. The company stands 106th in the ‘Forbes Global 2000’ rankings for 2017 – the top-most among Indian companies. It ranks 10th in LinkedIn’s ‘Top Companies Where India Wants to Work Now’ (2017). RIL’s activities span hydrocarbon exploration and production, petroleum refining and marketing, petrochemicals, retail and 4G digital services.

About Eros International Plc

Eros International Plc (NYSE: EROS) is a leading global company in the Indian film entertainment industry that acquires, co-produces and distributes Indian films across all available formats such as cinema, television and digital new media. Eros International Plc became the first Indian media company to list on the New York Stock Exchange. Eros International has experience of over three decades in establishing a global platform for Indian cinema. The Company has an extensive and growing movie library comprising of over 3,000 films, which include Hindi, Tamil, and other regional language films. The company also owns the rapidly growing OTT platform Eros Now. For further information please visit: www.erosplc.com.

About Jyoti Deshpande

Ms. Jyoti Deshpande has over 25 years of experience in media and entertainment across advertising, media consulting, television and film. She has been part of the leadership team of Eros International Plc since 2001 and as Group CEO & MD she has spearheaded Eros’s growth as a global leader in Indian filmed entertainment. Prior to joining Eros in 2001, Ms Deshpande has worked for 7 years in the field of advertising, media consulting and television with companies such as J Walter Thompson India, Mindshare, Zee Television and B4U Television. Ms. Deshpande has a Bachelor’s Degree in Commerce and Economics from Mumbai University and a Master’s Degree in Business Administration (MBA) from SPJIMR, Mumbai University.

Ms. Deshpande was featured in the prestigious Fortune India magazine’s 50 Most Powerful Women in Business (2017/2015) which celebrates the journeys and triumphs of women who not only impact their organizations but are also thought leaders in their industry. Ms. Deshpande was also featured in the list of Top 50 Most Powerful Women in Business by Business Today (2015). She was also recently awarded as one of the Women of the Decade for Innovation and Leadership by Women Economic Forum.


Eros International Plc
Mark Carbeck, +44 207 258 9909
Chief Corporate and Strategy Officer
Sloane & Company
Erica Bartsch, +1 212 446 1875

Global Immune Checkpoint Inhibitors Market 2018-2022 – Expected to Reach $25 Billion – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Immune Checkpoint Inhibitors Market Outlook 2022" report has been added to ResearchAndMarkets.com's offering.

The global immune checkpoint inhibitors market is anticipated to cross US$ 25 Billion by 2022.

The report provides a detailed analysis of the global immune checkpoint inhibitors market. The report also provides the current and forecasted market for immune checkpoint inhibitors.

The global immune checkpoint inhibitors market has been segmented on the basis of type of product into PD-1, PD-L1, and CTLA-4. According to the report, PD-1 segment was estimated to account for the largest share in 2016 due to entry of multiple pharmaceutical players in the PD-1 inhibitors market, increasing investments from various key pharmaceutical companies and active research with many pharmaceutical companies looking to launch there products.

Market Dynamics


  • Increasing Cancer Incidences
  • Immune Checkpoint Inhibitors Sales Driving the Market Growth
  • Growing Geriatric Population
  • High Healthcare Spending in Developed Economies
  • Strong Pipeline
  • Increasing Efficacy in a Wide Variety of Indications
  • Burgeoning Approval and Uptake of Immuno-Oncology Products


  • Increasing Number of Side-Effects Post Immunotherapy Treatments
  • Sky-High Development Costs of Cancer Immunotherapies
  • High Cost of Treatment
  • Lack of Awareness


  • Opdivo and Keytruda Presents Significant Growth Opportunity
  • Combination Therapies Could Lead to Substantial Increases in Survival
  • Small Companies Offering Huge Opportunities for Next Generation Immunotherapies

Key Topics Covered:

1. Research View

2. Research Methodology

3. Immune Checkpoint Inhibitors: Overview

4. Market Dynamics

5. Global Immune Checkpoint Inhibitors Market Outlook 2022

6. Global Immune Checkpoint Inhibitors Market, by Product Class

7. Application of Immune Checkpoint Inhibitors in Major Indications

8. Trends & Developments

9. Strategic Collaborations & Alliances in the Immune Checkpoint Inhibitors Market

10. Pipeline Analysis of Immune Checkpoint Inhibitors

11. Key Players Analysis

  • AstraZeneca Plc
  • Bristol-Myers Squibb
  • CureTech Ltd.
  • EMD Serono, Inc.
  • Genentech, Inc. (A Member of the Roche Group)
  • Merck & Co., Inc.
  • NewLink Genetics Corporation
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc

For more information about this report visit https://www.researchandmarkets.com/research/qhbmzx/global_immune?w=4.


Laura Wood, Senior Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs

2018 Global Antibody Drug Conjugates Drug Sales, Pipeline Analysis & Market Forecasts to 2023 – Efforts Towards Patent Protection to Drive ADC Market – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Antibody Drug Conjugates Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) & Global Market Forecasts to 2023" report has been added to ResearchAndMarkets.com's offering.

The Global Antibody Drug Conjugates Market is anticipated to witness a double digit growth during 2017-2023.

The report provides information about the current and future market scenario of the Global ADCs Market. The report also highlights the major drivers, such as increasing incidences of cancer and advances in linking technologies, for the Global Antibody Drug Conjugates Market. Furthermore, the report also gives information related to the commercially available ADCs such as ADCETRIS, Kadcyla, Mylotarg and Besponsa.

Moreover, few hindrances, such as high cost of production cost, lack of experienced manufacturers and regulatory challenges, which are slowing down the growth of the Global ADCs Market, have also been mentioned in the report. In addition, the report also highlights various trends and developments taking place in this market.

Market Dynamics


  • Rising Global Cancer Epidemics
  • Advances in Linking Technologies Re-Instills Hope in ADC
  • Efforts towards Patent Protection to Drive ADC Market
  • Increasing Demand for Antibody Drug Conjugates


  • Production Hurdles and Cost
  • Inadequacy of Experienced Manufacturers
  • Regulatory Challenges

Key Topics Covered:

1. Research View

2. Research Methodology

3. Antibody Drug Conjugate (ADC) - An Introduction

4. Global Antibody Drug Conjugates Market Outlook to 2023

5. Commercialized Antibody Drug Conjugates

6. Antibody Drug Conjugates Pipeline Analysis

7. Drivers and Challenges

8. Major Potential Antibody Drug Conjugates in Pipeline

9. Trends and Developments

10. Strategic Alliances in the Global Antibody Drug Conjugates Industry

11. Competitive Assessment

  • Bayer AG
  • Concortis Biotherapeutics
  • F. Hoffman-La Roche Ltd.
  • ImmunoGen, Inc.
  • Immunomedics, Inc.
  • NBE-Therapeutics
  • Oxford BioTherapeutics
  • Pfizer Inc.
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited

For more information about this report visit https://www.researchandmarkets.com/research/sf3fj6/2018_global?w=4.


Laura Wood, Senior Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs

ProPay® Brings Disbursement Fund Capabilities to China

Offers an easier way for U.S. businesses to disburse funds to UnionPay cardholders in mainland China

COLUMBUS, Ga.--(BUSINESS WIRE)--#China--ProPay, a TSYS® company, announced today the expansion of its global disbursement funds and commissions platform to UnionPay cardholders in mainland China. ProPay makes it simple for U.S. companies to distribute funds to consumers in mainland China using UnionPay International’s MoneyExpress program, which provides easy access to funds throughout the country.

Earlier this year, ProPay expanded its disbursement platform to support international payment processing and global commissions in 180 countries, and in more than 130 currencies. With the expansion of these capabilities to China, ProPay clients have even broader paying power.

“For companies that operate on a global scale, dealing with exchange rates, cross border fees and other financial hurdles can result in increased costs and frustration,” explained Dave Duncan, president of ProPay. “Unlike our competitors, ProPay has the ability to remove these roadblocks by offering a convenient, cost-effective approach. Our clients who conduct business in mainland China can now get their distributors paid quickly, and no hidden fees are incurred.”

ProPay’s enhancement to its global disbursements and commissions platform offers customers a variety of unique capabilities for disbursing funds to UnionPay cardholders in mainland China, including:

  • Disbursement of funds in near real-time (no longer than 12 hours), which is drastically shorter than typical bank transfers, which can take up to seven days
  • ProPay’s integration with UnionPay International eliminates the need for funding recipients to file government registration, allowing for immediate access to funds
  • UnionPay cardholders of 13 issuers in mainland China will receive the funds in RMB
  • Recipients can see the exact amount being deposited into their account at the time of the transaction (or in 12 hours or less, in some cases)
  • No fees on inbound deposits are assessed to the funding recipient
  • UnionPay is accepted widely throughout China, allowing recipients to spend funds almost anywhere in the country

“Retaining great consultants and distributors is the lifeblood of direct selling companies, and ensuring they’re paid quickly is vital to maintaining their loyalty,” said Mike Cottrell, vice president of ProPay. “We’re proud to offer our business customers a solution that ensures their distributors are getting paid on time and without hassle.”

For more information contact ProPay at 888.227.9856 or sales@propay.com, or visit www.propay.com/payouts.

About ProPay

Since 1997, ProPay has provided simple, secure and affordable payment solutions for organizations ranging from small, home-based entrepreneurships to multi-billion-dollar enterprises requiring complex payment solutions. ProPay’s ProtectPay® platform provides software integrators, payment facilitators and SaaS providers with all the tools necessary to easily implement payment processing. As a leading provider of complete end-to-end payment security solutions, ProPay helps reduce the client organization’s risk of sensitive payment data compromise. ProPay is a wholly owned subsidiary of TSYS (NYSE: TSS) and a leader in payment data security. For information, visit www.propay.com or call 888.227.9856.

About TSYS

TSYS® (NYSE: TSS) is a leading global payments provider, offering seamless, secure and innovative solutions across the payments spectrum — from issuer processing and merchant acquiring to prepaid program management. We succeed because we put people, and their needs, at the heart of every decision. It’s an approach we call ‘People-Centered Payments®’.

Our headquarters are located in Columbus, Ga., U.S.A., with approximately 11,500 team members and local offices across 13 countries. TSYS generated revenue of $4.9 billion in 2017, while processing more than 27.8 billion transactions. We are a member of The Civic 50 and were named one of the 2018 World's Most Ethical Companies by Ethisphere magazine. TSYS is a member of the S&P 500 and routinely posts all important information on its website. For more, visit tsys.com.


Media Relations:
Cyle Mims, 706-644-3110
Investor Relations:
Shawn Roberts, 706-644-6081
Scott Nelson, 801-341-5566

Santen Pharmaceutical to Leverage Medidata Edge CTMS to Drive Future Growth in Ophthalmic Clinical Development

Company adopts Edge CTMS in Japan as part of rapid global expansion

NEW YORK--(BUSINESS WIRE)--#clinicaltrials--Santen Pharmaceutical Co., Ltd, is expanding its use of the Medidata Clinical Cloud® with the adoption of Edge CTMS (Clinical Trial Management System) to support its clinical trial operations, in ophthalmology, across Japan, Asia, USA and the EU. Santen becomes the first sponsor to adopt Medidata Edge CTMS in the Japanese market.

Medidata is the leading global provider of cloud-based technology and data analytics for clinical research. As Santen strives to globalize its research and development operations, the company will deploy Edge CTMS to streamline trial activities, increase productivity and improve efficiency of trial execution.

Edge CTMS provides real-time visibility into clinical trial milestones, allowing Santen to evaluate operational effectiveness and implement changes rapidly. It also seamlessly integrates with Rave EDC, the industry-leading EDC solution, enabling Santen to dramatically speed trial execution by managing both study and trial data on a single unified platform.

“There is a growing demand to simplify, improve efficiency and create transparency across clinical trials. The Medidata Edge CTMS solution makes it possible for life science companies to achieve all three on our unified platform,” said Glen de Vries, Medidata president and co-founder. “We look forward to strengthening our relationship with Santen, and helping to streamline workflows across their R&D, globally.”

About Santen

As a specialized company dedicated to the ophthalmic field, Santen carries out research, development, marketing, and sales of pharmaceuticals. Santen is the market leader in Japan for prescription ophthalmic pharmaceuticals and sells products in approximately 60 countries. As a leading company in the field of ophthalmology, Santen aims to contribute to society by supplying valuable products and services to satisfy unmet medical needs. For more details, please see Santen’s website (www.santen.com).

About Medidata

Medidata's unified platform, pioneering analytics, and unrivaled expertise power the development of new therapies for over 1,000 pharmaceutical companies, biotech, medical device firms, academic medical centers and contract research organizations around the world. The Medidata Clinical Cloud® connects patients, physicians and life sciences professionals. Companies on the Medidata platform are individually and collaboratively reinventing the way research is done to create smarter, more precise treatments. For more information: www.mdsol.com


Medidata Solutions
Betsy Frank, +1 917-522-4620
Erik Snider, +1 646-362-2997

Takeda Deepens Commitment to Develop Innovative Treatments for Neurological Diseases

Collaboration with Wave Life Sciences Ltd. to discover and develop best-in-class antisense oligonucleotides for potential treatment of genetically-defined neurological diseases

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it has entered into a research, development and commercial collaboration and multi-program option agreement with Wave Life Sciences Ltd. (Wave) to develop antisense oligonucleotides for genetically-defined neurological diseases. This partnership supports Takeda’s externalization strategy, which focuses on collaborations that complement its internal pipeline of programs, and represents the next generation of innovative therapies to treat diseases with no current treatment options.

“Takeda is deeply committed to pursuing innovative approaches in neuroscience research and development,” said Emiliangelo Ratti, Head, Neuroscience Therapeutic Area Unit at Takeda. “Our collaboration with Wave will further enable our focus to accelerate the development of transformational therapies for patients for whom there are currently no treatments available.”

The first component of the collaboration with Wave will focus on programs targeting Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS) (commonly referred to as Lou Gehrig’s disease), frontotemporal dementia (FTD) and spinocerebellar ataxia type 3 (SCA3). Wave is developing oligonucleotide therapeutics to target diseases that have been historically difficult to treat with small molecules or biologics. Their molecules are designed to reduce the expression of disease-promoting proteins or to transform the production of dysfunctional mutant proteins into the production of functional proteins, with the potential of treating the targeted disease. The first component of this collaboration will investigate the following potential therapies with the option to co-develop and co-commercialize after demonstration of clinical proof of mechanism:

  • WVE-120101 and WVE-120102, which selectively target mutant huntingtin and are currently in Phase 1b/2a clinical trials for the treatment of HD
  • WVE-3972-01, which targets C9ORF72 and is expected to be evaluated in clinical studies for the treatment of ALS and FTD beginning in Q4 2018
  • Program targeting ATXN3 for the treatment of SCA3

The second component of the collaboration provides Takeda with the rights to exclusively license multiple preclinical programs targeting other neurological disorders including Alzheimer’s disease and Parkinson’s disease. At any one time during a four-year term, the companies may collaborate on up to six preclinical programs.

“At Takeda, we are focused on partnering with companies that share our research focus and commitment to deliver transformative medicines to patients,” said Daniel Curran, M.D., Head, Center for External Innovation at Takeda. “Wave’s expertise in optimizing oligonucleotides offers a complementary approach to programs that Takeda is currently pursuing for neurological disorders, maximizing our potential for success, and their pipeline and focus are closely aligned with our own.”

This collaboration with Wave is part of Takeda’s overall partnership strategy and deepened commitment in neuroscience, which also includes recently signed collaboration agreements with Mindstrong Health to explore the development of digital biomarkers for selected mental health conditions, and Denali Therapeutics, a company with an innovative platform technology for transporting antibodies into the brain, to develop and commercialize therapies for neurodegenerative diseases.

About Takeda Neuroscience

Neuroscience is a core therapeutic area for Takeda. Our aspiration is to provide innovative medicines for targeted patient populations suffering from neuropsychiatric disorders for whom there are no treatments available. We identify targets either genetically linked with specific neuropsychiatric disorders or with high association to the disease pathophysiology, design and operationalize clinical trials in novel ways in an effort to overcome historical challenges, and collaborate with patients, academic institutions, pharmaceutical and biotechnology partners, payors, regulators and prescribers to integrate their unique expertise and perspective. Takeda’s current portfolio consists of four approved medicines to treat adults with Major Depressive Disorder (MDD), Alzheimer’s-type dementia, insomnia and multiple sclerosis. In addition, there are many novel compounds in clinical development for targeted patient populations.

About Takeda Pharmaceutical Company

Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries. For more information, visit https://www.takeda.com/newsroom/.

Takeda’s Forward-Looking Statements

This press release contains “forward-looking statements.” Forward-looking statements include all statements other than statements of historical fact, including plans, strategies and expectations for the future, statements regarding the expected timing of filings and approvals relating to the transaction, the expected timing of the completion of the transaction, the ability to complete the transaction or to satisfy the various closing conditions, future revenues and profitability from or growth or any assumptions underlying any of the foregoing. Statements made in the future tense, and words such as “anticipate,” “expect,” “project,” “continue,” “believe,” “plan,” “estimate,” “pro forma,” “intend,” “potential,” “target,” “forecast,” “guidance,” “outlook,” “seek,” “assume,” “will,” “may,” “should,” and similar expressions are intended to qualify as forward-looking statements. Forward-looking statements are based on estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict. Investors and security holders are cautioned not to place undue reliance on these forward-looking statements.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Some of these risks and uncertainties include, but are not limited to: required regulatory approvals for the transaction may not be obtained in a timely manner, if at all; the conditions to closing of the transaction may not be satisfied; competitive pressures and developments; applicable laws and regulations; the success or failure of product development programs; actions of regulatory authorities and the timing thereof; changes in exchange rates; and claims or concerns regarding the safety or efficacy of marketed products or product candidates in development.

The forward-looking statements contained in this press release speak only as of the date of this press release, and neither Wave nor Takeda undertake any obligation to revise or update any forward-looking statements to reflect new information, future events or circumstances after the date of the forward-looking statement. If one or more of these statements is updated or corrected, investors and others should not conclude that additional updates or corrections will be made.


Kelly Schlemm, +1-617-551-8865

LetinAR Co., Ltd. to Exhibit at Mobile World Congress 2018

GANGNAM-GU, South Korea--(BUSINESS WIRE)--Press Kit Materials are Available at: http://www.tradeshownews.com/events/mobile-world-congress-2018/letinar-co-ltd/

Company:   LetinAR Co., Ltd.
Booth/Stand: 5G31
Event: Mobile World Congress 2018
Feb 26 - Mar 1, 2018
Barcelona, ES









About LetinAR Co., Ltd.

LetinAR Co., Ltd. attending MWC for the first time challenges long-standing problems of Augmented Reality by introducing novel optical technology. At MWC 2018, the quadrupled high-resolution demos compared to CES 2018 will be revealed, and by arranging a private meeting, partners will be introduced to current developing next-generation lenses. Augmented Reality glasses we’ve created at LetinAR, is thin enough and small enough to be worn like a pair of conventional eyeglasses. Users can see the sharp and clear virtual image and real image at the same time with our glasses. LetinAR Co., Ltd was founded in October 2016 and is based in Seoul, South Korea.


LetinAR Co., Ltd.
PR Contact
Jeewon Rho, +8210-2239-6211
IR Contact
Jaehyeok Kim, +8210-5020-4223

Global Cloud Xchange & RCOM Sweep Honors at the ‘Times Ascent Dream Companies to Work for Awards’ by World HRD Congress

MUMBAI, India--(BUSINESS WIRE)--Global Cloud Xchange (GCX) & Reliance Communications (RCOM) received top honor in the ‘Institution Building Category’ at the recently-concluded Times Ascent Dream Companies to Work 2018 Awards organized by World HRD Congress. Bill Barney, CEO, GCX & RCOM was also honored in the ‘CEO with HR Orientation’ along with Gina Haspilaire, Chief Human Resources Officer, GCX & RCOM who was presented with the Femina Exemplary Leadership Award at the ceremony.

The Times Ascent Dream Companies to Work 2018 Awards, now in its 7th year, have become a defining accolade for organizations, providing recognition to path-breaking efforts made in various categories. Award winners were chosen by an independent expert panel of judges from across industry sectors, with the underlying objective of recognizing and celebrating excellence.

“It is an honor to be recognized for our continuous efforts towards keeping our employees inspired and motivated so that they deliver their best. At GCX and RCOM we are passionate about our work and believe that success is delivered as a team. Our employees are the company’s most valuable assets. Our sincere gratitude to Times Ascent Dream Companies for these prestigious awards,” said Bill Barney.

“We are extremely thrilled with the recognitions we have received from Times Ascent Dream Companies and it is a proud moment for all of us at GCX and RCOM to see our contributions to the industry being recognized at such a prestigious platform. Our focus continues to be transforming our institution building capacities and strengthening human resource orientation to achieve excellence in our business,” Gina Haspilaire added.

The awards ceremony was held in Mumbai and attended by leading corporations, celebrating the achievements of all the winners with an evening of fine dining and entertainment.


Global Cloud Xchange
Kumar Abhijeet, +91 8080334332

Seoul Semiconductor Successfully Invalidates Everlight’s Patent in the United Kingdom and Holds Everlight Responsible for Paying Significant Litigation Costs to Seoul

ANSAN, South Korea--(BUSINESS WIRE)--$KOSDAQ046890 #IP--On February 20, 2018, Seoul Semiconductor Co., Ltd. (“Seoul”) announced that Seoul has won the patent invalidity litigation action that was filed against Everlight Electronics Co., Ltd. (“Everlight”) in the United Kingdom.

Everlight’s patent, EP (UK) 1169735, which was invalidated as a result of Seoul’s suit, relates to an LED package structure for thermal dissipation. Everlight purchased this patent from a U.S. company in 2017. Recently, Everlight filed a patent infringement litigation based on a foreign counterpart of this patent against its competitor, Bridgelux, Inc., in a U.S. federal court.

Last year, Seoul filed an invalidation litigation against this Everlight patent in the Patent Court of the United Kingdom. After intensive proceedings in the UK court, Everlight abandoned its defense and acknowledged in the court proceeding that its patent is invalid and that it is responsible for reimbursing Seoul for its litigation costs.

On February 14, 2018, based on Everlight’s admissions, the UK Patent Court issued an order declaring that Everlight’s patent should be revoked. The Court also ordered that Everlight must pay approximately $1 million dollars (£712,247.10) in litigation costs to Seoul based upon Everlight’s stipulation.

This victory represents one of the key tenets of Seoul’s IP strategy – preventing an abuse of patents that should never have been granted by pre-emptively invalidating such patents.

Seoul has also taken the offensive in its IP enforcement to prevent infringement of its own patent rights. Currently, Seoul is enforcing certain of its patent rights against a distributor of Everlight LED products. During the past year, Seoul has launched two patent infringement lawsuits in Germany against Mouser Electronics (“Mouser”), a global distributor of Everlight LED products. In addition, Seoul recently filed a new patent litigation against Mouser for the sale of allegedly infringing Everlight products in Italy. Following SSC’s latest enforcement action in Italy, Mouser appears to have removed all Everlight products from its distribution list of products worldwide.

About Seoul Semiconductor:
Seoul Semiconductor develops and commercializes light emitting diodes (LEDs) for automotive, general illumination, specialty lighting, and backlighting markets. As the fourth-largest LED manufacturer globally, Seoul Semiconductor holds more than 12,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; WICOP – a simpler structured package-free LED which provides market leading color uniformity, cost savings at the fixture level with high lumen density and allows design flexibility; NanoDriver Series – the world’s smallest 24W DC LED Drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, includes all AC LED-related technologies from chip to module and circuit fabrication, as well as multi-junction technology (MJT); and nPola, a new LED product based on GaN-substrate technology that achieves more than ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers more than 90% NTSC.

For more information about Seoul Semiconductor, please visit http://www.seoulsemicon.com

# Trademarks
Wicop and Acrich are trademarks of Seoul Semiconductor Co., Ltd.


Seoul Semiconductor Europe GmbH
Ariane Heim
Tel: +49 (0)89 450 3690-0
Email: press.eu@seoulsemicon.com
North America
Seoul Semiconductor Inc.
David Cox
Tel: +1 (919) 410-9856
Email: David.cox@seoulsemicon.com
Seoul Semiconductor Co., Ltd
Jake Jung
Tel: +82 070.4391.8270
Email: pr@seoulsemicon.com

Ezaki Glico to Announce the Acquisition of American Chocolate Manufacturing Company, TCHO Ventures, Inc.

OSAKA, Japan--(BUSINESS WIRE)--Ezaki Glico Co., Ltd. (“Ezaki Glico”) (TOKYO:2206) has announced the final agreement to acquire America’s award-winning craft chocolate company, TCHO Ventures, Inc. (CEO: Marcel Bens, Head office: California, USA, “TCHO”).

The U.S. chocolate market is estimated at approximately USD 18.9 billion per year, and has been growing at an annual rate of 2% (according to the 2017 research by Euromonitor International).
TCHO, a premium craft chocolate company known for its superior quality chocolate, has earned strong brand recognition in the US market and particularly amongst millennials, the generation with the highest purchase intent. The overall market in the premium chocolate category is expecting strong continued growth, and by acquiring TCHO and entering this market, Ezaki Glico aims to enhance its chocolate business.

About TCHO Ventures, Inc.
The San Francisco Bay area based company is majority owned by Emil Capital Partners, a Growth and Venture Capital firm backed by European retail giant Tengelmann Group.

(1) Company Name   TCHO Ventures, Inc.
(2) Location Berkeley, California, USA
(3) Representative Marcel Bens (CEO)
(4) Foundation December, 2005
(5) Establishment July, 2007
(6) Business Area Manufacturing and selling chocolate snacks
(7) Number of Employees 37 employees (As of November 2017)
(8) URL


(9) Core Products  

70g Bar, 8g Bar, 140g Bites


About Ezaki Glico
Ezaki Glico Co., Ltd. (Ezaki Glico) is a leading food company headquartered in Osaka, Japan. It has 11 business locations and 23 group companies in Japan, and 12 subsidiaries in nine countries. Ezaki Glico operates a total of 19 plants and has 5,210 employees over the world. Since the launch in 1922 of the nutritious and fortified Glico caramel in its distinctive red box, the business activities of Ezaki Glico have adhered to the corporate philosophy of "Enhancing Public Health Through Food." Upon the 70th anniversary of Ezaki Glico in 1992, this same spirit and dedication has been incorporated into the revised corporate philosophy of "A Wholesome Life in the Best of Taste." Glico caramel – the company's first product – incorporates the innovative creativeness of Mr. Riichi Ezaki, the company's founder. From the beginning, all personnel working for the company have been dedicated to further enhancing people's health and quality of life. This has led to the expansion of business lines beyond confectionery to include ice cream products, processed foods, desserts, milk products, baby formula, food ingredients and ingredients for cosmetic and health products. Ezaki Glico has generated consolidated sales of JPY353.2 billion in FY 2016. Ezaki Glico’s business covers 30 countries and areas in Asia, the South Pacific, North America and Europe. In USA, Ezaki Glico USA Corporation was founded in February 2003 in Irvine, California to sell products such as Pocky and PRETZ. https://www.glico.com/us/


For all media inquiries
Burson-Marsteller Tokyo
Misato Kagami / Vanessa Kiyomiya, (+81) 3-3264-6701

Mitsubishi Electric’s New Integrated-automation Factory to Produce Vacuum Interrupters and Vacuum Circuit Breakers

Built for innovative, efficient IoT-based production based on “e-F@ctory” concept

TOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it has completed construction of an integrated-automation factory for the production of vacuum interrupters and circuit breakers at its Power Distribution Systems Center in Marugame, Japan. The new factory will deploy Mitsubishi Electric’s e-F@ctory concept of integrated automation based on IoT technologies to achieve high efficiency, high productivity and minimized cost. Combined sales of vacuum interrupters and vacuum circuit breakers are expected to rise to 12 billion yen by 2025.

The company’s e-F@ctory concept makes use of cutting-edge technologies to visualize information and integrate with high-level manufacturing-execution systems for advanced production. The new factory leverages this know-how to unify production information, from orders to assembly to shipments, for enhanced productivity and product quality. The e-F@ctory concept will also be used to improve cycle speeds and shorten lead times.

The integrated-automation production line’s uptime will be maximized through the partial introduction of automatic assembly and testing devices for vacuum interrupters and vacuum circuit breakers, which previously had been decentralized within the Power Distribution Systems Center.

The factory is the first to deploy Mitsubishi Electric’s D-SMiree System* for medium- and low-voltage direct-current distribution systems of voltages up to 1,500V DC. In addition, the new factory will deploy advanced energy-saving equipment and energy-loss visualization technologies to minimize its environmental footprint and energy consumption.

The global demand for vacuum interrupters and vacuum circuit breakers is foreseen expanding over the mid to long term due to the increasing introduction of renewable-energy facilities and the upgrading of existing electrical distribution equipment at power utilities, railways and factories. The new factory gives Mitsubishi Electric the necessary production capacity to meet current demand and over the longer term will provide the necessary competitiveness to expand sales share and enter new markets for vacuum interrupters and vacuum circuit breakers.

For the full text, please visit: www.MitsubishiElectric.com/news/

* D-SMiree ─ Diamond-Smart Medium Voltage Direct Current Distribution Network System for Innovative Reliable Economical Ecology


Mitsubishi Electric Corporation
Customer Inquiries
Power Distribution Systems Center
Media Inquiries
Niels Meinke, +81-3-3218-2831
Public Relations Division

Kitsault Energy (KE) Announces Plan to Turn Waste into Energy in India and Canada

VANCOUVER, British Columbia & OTTAWA, Ontario & NEW DELHI & MUMBAI, India--(BUSINESS WIRE)--#AlternativeEnergy--Kitsault Energy (KE) is pleased to announce plans to turn waste into energy in India and Canada using a Proprietary and Patented process. The waste includes legacy waste wood from pulp and paper plants, municipal solid waste, road waste, food waste, animal manure, and invasive species such as Gando Baval in India. The process produces high-energy water-repellent solid biofuel that burns with no residual ash making it ideal for coal replacement in the steel and cement industries, who together are responsible for 10% of fossil-fuel green house gas emissions worldwide. KE's process is a green solution to landfills and holding ponds that transforms the energy of decaying bio-waste into a viable coal alternative, which offsets fossil carbon dioxide, reduces methane off-gassing, and eliminates prions when used to treat animal manure. The process works especially well with high-moisture bio-waste, avoiding costly pre-drying.

Krishnan Suthanthiran, President & Founder of KE says, "Kitsault Energy invites municipalities, companies, and governments with a green vision of the future to join us. Climate change, the expected cost of carbon in tomorrow’s economy, the desire to get off fossil fuels, the need to develop alternative energy sources, the ever-growing problem of landfills, and the drive for a sustainable future are all compelling reasons to join us. We offer a small step in the right direction."

Kitsault Energy was founded to develop the energy riches of the Pacific Northwest of Canada by Krishnan Suthanthiran, who also is the President and Founder of the TeamBest Companies devoted to providing affordable healthcare. Reducing pollution and developing green energy sources is part of KE’s prescription for a healthy planet.

For more information about Kitsault Energy, please visit www.kitsaultenergy.com/press. To read Krish Suthanthiran’s bio, please visit www.teambest.com/about_bio.html.

Canada Office (BC): 8765 Ash Street, Unit 7, Vancouver, BC V6P 6T3 Canada

Canada Office (ON): 413 March Road, Ottawa, Ontario K2K 0E4 Canada

U.S. Office (HQ): 7643 Fullerton Road, Springfield, Virginia 22153 USA


Kitsault Energy
Krishnan Suthanthiran, +1 703-451-2378
President & Founder